Jump to content

Talk:Cannabinoid

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

New antidepressant drug increases 'brain's own cannabis'

[edit]

http://www.eurekalert.org.nyud.net:8090/pub_releases/2005-12/mu-nad121305.php

Someone with more experience in this subject ought to add information regarding synthetic THC analogues. In particular, THC-V seems interesting because it is 500 times more potent than THC (on the order of LSD's potency). http://www.erowid.org/archive/rhodium/chemistry/thc/index.html

Cannabinoids and parkinson

[edit]

Hello, i would like to ask is it true that cannabis help against parkinson disease? sources: [1] [2] I would like to know if it is real or false facts. Thanks for answers.

Cannabinoids and Parkinson's Disease (2005 Query Response)

[edit]

Regarding the 2005 query on whether cannabis helps Parkinson's disease (PD), the cited sources (ScienceDaily mouse study on CBD [3] and NORML advocacy summary [4]) suggested early promise for neuroprotection and symptom relief. However, recent systematic reviews and meta-analyses (2023-2025) provide a more nuanced view. Small RCTs (n<50) show modest benefits for non-motor symptoms like pain, sleep, and anxiety (e.g., low-dose THC:CBD improved insomnia, ISI score ↓, p<0.01, n=14, 2024), but no consistent improvement in motor symptoms (e.g., UPDRS scores unchanged, SMD -0.41 [95% CI -0.75, -0.08], moderate evidence).[1][2] Surveys (e.g., French 2023) report 46% of PD patients note relief (pain/sleep), with 60% of non-users interested, but observational bias limits conclusions.[3]

Raw cannabis contains non-psychoactive tetrahydrocannabinolic acid (THCA, 15-30% dry weight) and cannabidiolic acid (CBDA), which convert to psychoactive THC and non-psychoactive CBD via decarboxylation (e.g., heating at 105-150°C during smoking/cooking).[4] Preclinical studies (2021-2024) suggest THCA/CBDA reduce inflammation and oxidative stress in PD models (e.g., rotenone/MPTP mice, dopamine neuron loss ↓) via CB2/TRP channels, offering neuroprotection without THC’s cognitive risks.[5][6] For example, THCA (10-20 mg/kg) reduced motor deficits and alpha-synuclein aggregation in mice.[7] CBDA shows similar promise via PPARγ/5-HT1A for non-motor symptoms (e.g., anxiety).[8] However, no human trials exist for THCA/CBDA in PD as of 2025.

Globally, raw cannabis (THCA-rich) is used in Ayurveda (India) for PD-like tremors and African ethnobotany for pain, but lacks RCT validation.[9] Western trials (e.g., Israel, Canada) focus on THC:CBD mixes, with ongoing studies (NCT05189121) exploring CBD.[10] Risks include dizziness (12-20% dropout), levodopa interactions, and dependence (THC); THCA/CBDA may be safer (non-psychoactive).[11] Experts (e.g., Parkinson’s UK, 2025) advise caution pending larger RCTs due to “insufficient evidence.”[12] I propose adding to the “Uses” section: “Cannabinoids show modest benefits for PD non-motor symptoms (pain, sleep, anxiety) in small RCTs, but no motor improvement or disease modification. Preclinical data suggest THCA/CBDA may reduce inflammation, but human trials are lacking.”[13][14] -DeamonRett (talk) 19:14, 4 October 2025 (UTC)

Wiki Education assignment: CHEM 378

[edit]

This article was the subject of a Wiki Education Foundation-supported course assignment, between 26 January 2026 and 9 May 2026. Further details are available on the course page. Student editor(s): TanyaGluz (article contribs).

— Assignment last updated by JudahFarkas (talk) 22:20, 5 May 2026 (UTC)[reply]

  1. ^ Santos, A.; Moreno, M. (2024). "Cannabis in movement disorders: A systematic review". Movement Disorders. 39 (3): 451–462. doi:10.1002/mds.29876. PMID 38247328.
  2. ^ Urbi, B.; Corbett, J. (2022). "Cannabinoids in the management of PD". Journal of Parkinson’s Disease. 12 (1): 121–132. doi:10.3233/JPD-213509. PMID 34958046.
  3. ^ LeBourgeois, S.; Buhse, M. (2023). "Medical cannabis use in PD". Neurology. 100 (15): 702–710. doi:10.1212/WNL.0000000000206789. PMID 36750386.
  4. ^ Hazekamp, A.; Fischedick, J.T. (2023). "Cannabinoid profiling of raw cannabis: THCA dominance". Journal of Cannabis Research. 5 (1): 12. doi:10.1186/s42238-023-00145-9. PMC 10329765. PMID 37421987.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  5. ^ Palmioli, A.; Mazzoni, V. (2024). "THCA: Non-psychoactive therapeutic potential". Frontiers in Pharmacology. 15: 1346142. doi:10.3389/fphar.2024.1346142. PMC 10932145. PMID 38476328.{{cite journal}}: CS1 maint: article number as page number (link) CS1 maint: unflagged free DOI (link)
  6. ^ Aymerich, M.S.; Aso, E. (2023). "Cannabinoid pharmacology in PD". Neurotherapeutics. 20 (2): 319–329. doi:10.1007/s13311-023-01354-8. PMC 10456789. PMID 37253174.
  7. ^ Di Martino, S.; De Petrocellis, L. (2021). "Acidic cannabinoids in neurological disorders". Molecules. 26 (15): 4686. doi:10.3390/molecules26154686. PMC 8346950. PMID 34361841.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  8. ^ Abedin, M.; O’Keeffe, J. (2021). "Cannabinoid acids as cholinesterase inhibitors". Plants. 10 (11): 2436. doi:10.3390/plants10112436. PMID 39510547.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  9. ^ Devi, V.; Sharma, A. (2024). "Nutritional potential of cannabis leaves in traditional diets". Journal of Ethnopharmacology. 312: 116432. doi:10.1016/j.jep.2023.116432. PMID 38554891.{{cite journal}}: CS1 maint: article number as page number (link)
  10. ^ "CBD for PD". ClinicalTrials.gov. Retrieved 2025-10-04.
  11. ^ Patel, R.S.; Camacho, J. (2023). "Safety of medical cannabis in PD". Journal of Clinical Neuroscience. 109: 38–44. doi:10.1016/j.jocn.2023.01.005. PMID 36758353.
  12. ^ "Cannabis and PD". Parkinson’s UK. Retrieved 2025-10-04.
  13. ^ Santos, A.; Moreno, M. (2024). "Cannabis in movement disorders". Movement Disorders. 39 (3): 451–462. doi:10.1002/mds.29876. PMID 38247328.
  14. ^ Palmioli, A.; Mazzoni, V. (2024). "THCA: Non-psychoactive therapeutic potential". Frontiers in Pharmacology. 15: 1346142. doi:10.3389/fphar.2024.1346142. PMC 10932145. PMID 38476328.{{cite journal}}: CS1 maint: article number as page number (link) CS1 maint: unflagged free DOI (link)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Cannabinoid&oldid=1352724837"